Five years of implementation of guidelines in hematology and transfusion medicine in Brazil  by de Souza, Carmino Antonio
EF
h
C
a
b
I
H
t
(
G
o
p
s
S
b
b
m
a
t
s
t
g
a
r
t
R
w
t
t
q
c
m
l
C
h
1
rrev bras hematol hemoter. 2014;36(3):165–166
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
www.rbhh.org
ditorial
ive years of implementation of guidelines in
ematology and transfusion medicine in Brazil
armino Antonio de Souzaa,b,∗Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
Associac¸ão Brasileira de Hematologia e Hemoterapia (ABHH), Rio de Janeiro, RJ, Brazil
Conﬂicts of interestn 2009, the Associac¸ão Brasileira de Hematologia e
emoterapia (ABHH) started to participate in an impor-
ant mission proposed by the Associac¸ão Médica Brasileira
AMB) and the Conselho Federal de Medicina named “Project
uidelines”. This project had already been adopted by some
ther specialties. It aims to determine diagnostic, monitoring,
revention and therapeutic practices according to the best
cientiﬁc evidence available in the international literature.
ome attempts had already been made within hematology,
ut without systematization or continuity. Thus the ABHH
rought together a group of experts representative of the
ost important teaching and research institutions of Brazil
nd from the most varied areas of knowledge in hematology
o discuss diverse issues. After training, this group prepared
everal guidelines from the results of systematic investiga-
ions of the literature. Seventeen priority themes, working
roups and their coordinators were deﬁned as were the start
nd end dates for each issue. It was decided that all the
eports would be published in Portuguese in the journal of
he Associac¸ão Médica Brasileira (RAMB) and in English in the
evista Brasileira de Hematologia e Hemoterapia (RBHH). The
orking methodology included regular meetings between
he group of researchers and those who were carrying out
he systematic reviews of the literature. The most important
uestions were identiﬁed by experts of different ﬁelds within
linical hematology, pediatric hematology and transfusion
edicine. The ﬁrst set of guidelines, completed and pub-
ished in 2012, was related to chronic myeloid leukemia,1 an
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eserved.uncommon disease, but one with a modern research and
therapeutic model in oncology and hematology that uses
several generations of tyrosine kinase inhibitors. This set
of guidelines was fundamental to revise national treatment
protocols and allow access to these drugs through health
insurers. Guidelines on other important diseases followed
including those on multiple myeloma,2 primary immune
thrombocytopenia in children and adolescents3,4 and acute
promyelocytic leukemia.5 Other guidelines are currently being
completed and will be published in future issues of the RBHH.
The dominion of the methodology to prepare these guidelines
in Brazil has contributed signiﬁcantly to all levels of educa-
tion, to research and to the development of public policies
of access to diagnoses and therapeutic advancements. This
justiﬁes the great effort made by the ABHH and members. We
will continue to work to prepare other guidelines and update
the existing ones. This commitment has the goal of offering
the best and most relevant scientiﬁc data for the good of our
patients and our society. In addition, it aims to allow that
our actions, together with the regulatory agencies and the
incorporation of new technologies, are always supported by
the best scientiﬁc evidence available and, with this, reduce
any kind of conﬂict of interest that may exist.Centro de Hematologia e Hemoterapia de Campinas, Rua Carlos
ito de Barão Geraldo, Campinas, SP, Brazil.
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